HBIO Harvard Bioscience Inc. posts 100 percent Q4 2025 EPS miss vs estimates, shares rise 3.72 percent in today's trading. - Most Discussed Stocks

Clinical OMICsPioneering Innovation in Transplant Diagnostics

FierceBiotechRoche nabs EU approval on label expansions for companion dx platform

FierceBiotechGenentech executes another round of layoffs, with 3 VPs axed

ScienceLaser-boosted microscopes could reveal new drug targets, sharpen views inside cells

ScienceThe ocean current that warms Europe may be more resilient than feared

Clinical OMICsCyclana Bio Is Exploring the Extracellular Matrix to Treat Endometriosis

FierceBiotechAI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds

Clinical OMICsHigher Vitamin C Levels in Blood Linked to Healthier Aging Brains

Clinical OMICsStopping Neurodegeneration in Place with Vaccines

Clinical OMICsRemote Monitoring Benefits Unclear After Hospitalization for Serious Infection

FierceBiotechNovo reports data breach, tells clinical trial patients to 'remain vigilant'

Endpoints NewsThe seeming inevitability of rising healthcare costs